Navigation Links
AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Date:6/17/2013

NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). High-risk CLL patients are those with deletions of chromosome 17p or whose disease is refractory to fludarabine therapy. These data were presented at the 18th Congress of the European Hematology Association (EHA) in Stockholm, Sweden.

This Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199/GDC-0199 in patients with relapsed/refractory CLL and NHL. Secondary objectives included preliminary efficacy, including objective response rate, duration of response, time to progression, progression-free survival and overall survival. 

"New treatment options are critically needed for patients with hard-to-treat cancers including high risk CLL and MCL," said Gary Gordon, M.D., divisional vice president, oncology clinical development, AbbVie. "The preliminary data presented at EHA further support the ongoing clinical trial program for ABT-199/GDC-0199 via the BCL-2 pathway."

CLL Arm
As of April 2013, 56 patients have enrolled in the CLL arm of the Phase I trial, and 40 patients are currently active. Study participants were given a single oral dose of ABT-199/GDC-0199, followed by six days without medication, before continuous once-daily dosing. Due to concerns over tumor lysis syndrome (TLS), the initial dose was reduced and daily dosing was modified. Single-age
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 Nevro Corp. (NYSE: ... is providing innovative evidence-based solutions for the treatment of ... presenting at the Morgan Stanley Global Healthcare Conference on ... Nevro management is scheduled to present at ... a live audio webcast, accessible in the "Investors" section ...
(Date:9/3/2015)... , Sept. 3, 2015  WellCare Health Plans, ... Drew Asher , senior vice president and chief financial ... Securities 2015 Healthcare Conference on Wednesday, September 9, 2015, ... will be webcast live. In addition, a replay of ... the live broadcast. Both the live broadcast and the ...
(Date:9/3/2015)... , Sept. 3, 2015  Ascendis ... clinical stage biotechnology company that applies its ... medical needs, today announced plans to present ... Wells Fargo Healthcare Conference in BostonDate: , ... , Bank of America Merrill Lynch Global ...
Breaking Medicine Technology:Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... , ... 2008 amounted to over $1 billion in the European Union ... inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. ... fresh recommendations and treatment guidelines that call for using dopamine ...
... 8 Supermarket retailer Giant Eagle® Inc., is receiving an ... at the 12th Annual Cheers Awards reception held in Las ... have set a superlative standard of excellence for others to ... events. , The Giant Eagle Pharmacy ...
Cached Medicine Technology:Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 3Giant Eagle(R) Pharmacy Receives Award for Operational Excellence 2
(Date:9/3/2015)... ... September 03, 2015 , ... ... privately held medical technology company that will bring low-cost cancer pre-screening tests to ... , Preora’s proprietary and automated technology platform detects and measures cellular changes at ...
(Date:9/3/2015)... ... September 03, 2015 , ... William Mattar Law Offices is known for ... does not stop at any certain demographic or segment of the population. Because ... fifteen- and ten-second TV commercials. , The closed captioning will allow people with hearing ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... partner for the Academy of Integrative Health & Medicine (AIHM) Interprofessional Fellowship in ... of Tieraona Low Dog, MD, an internationally renowned educator, physician and thought leader ...
(Date:9/3/2015)... ... September 03, 2015 , ... E-Volve Health, ... leading national healthcare solutions organization, to provide electronic medical record (EMR) consulting services ... Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR consulting, custom ...
(Date:9/3/2015)... TX (PRWEB) , ... September 03, 2015 , ... ... pre-conference workshops included in Patient Experience Conference 2016, to be held April 13-15 ... non-provider or vendor hosted event bringing together the collective voices of healthcare leaders, ...
Breaking Medicine News(10 mins):Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3
... Tampa, Fla. (July 1, 2009) The frontiers of ... current issue of Cell Transplantation (Vol. 18 ... . Two studies are highlighted, one by a Brazil-based ... cell delivery methods following myocardial infarction, and a second ...
... , , , New study reports on posterior ... ROSEMONT, Ill., July 1 While major advances have been made in ... and reconstruction, a literature review published in the July 2009 issue of ... Orthopaedic Surgeons ( JAAOS ) finds that there must ...
... , Dedicated to advancing scientific research in regenerative medicine ... of universities, life sciences companies, health care investors, and ... therapies united today to launch the Alliance for Regenerative ... Washington, DC, the Alliance is dedicated to promoting regulatory, ...
... ET) Tufts dental researchers conducted a three-year follow-up study ... gums and found that complete root coverage the goal ... regeneration application, developed at Tufts, reduces the considerable pain and ... six patients is published in the July 2009 issue of ...
... Hospital has uncovered the biological effects of a novel ... for hormonal therapy for breast cancer. The study is ... Endocrinology. This new study by Edward Filardo, ... work by the group that linked the transmembrane receptor, ...
... early arthritis , , ROSEMONT, Ill., July 1 ... The condition occurs when a hip joint is shallow, unstable or when ... of developing arthritis of the hip as a ... of The Journal of Bone and Joint Surgery (JBJS) ...
Cached Medicine News:Health News:Cell transplantation and cardiac repair 2Health News:Cell transplantation and cardiac repair 3Health News:The 'Other' Cruciate Ligament: Newer Treatments for PCL Tears 2Health News:The 'Other' Cruciate Ligament: Newer Treatments for PCL Tears 3Health News:Alliance for Regenerative Medicine Launches 2Health News:New treatment for receding gums: No pain, lots of gain 2Health News:New treatment for receding gums: No pain, lots of gain 3Health News:Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer 2Health News:Infants Should Be Screened for Hip Trouble 2Health News:Infants Should Be Screened for Hip Trouble 3
... Catheter is indicated for balloon ... of a coronary artery or ... purpose of improving myocardial perfusion. ... also designed to provide distal ...
...
14mm from Mid-Screw to Tip, Slightly Curved, Sharp Tips; overall length 110mm; Stainless Steel....
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: